Catalysis

CompanySpain

Catalysis develops 3 assets, the furthest in phase 3, no development reported (Diamel in insulin resistance). Mostly supplement and small molecule; based in Spain.

3
Assets
Furthest stage
Phase 3, no development reported
8
Trials
13
Signals

Pipeline

3
  • Diamel

    Phase 3, no development reported, Supplement, insulin resistance, metabolic dysfunction-associated steatohepatitis

  • glycyrrhizin

    Inhibits HMGB1 activity and has anti-inflammatory and antiviral effects.

    Phase 3, no development reported, Small molecule, papilloma viral infection, CIN1

  • Viusid

    Phase 3, no development reported, Supplement, chronic hepatitis c, cirrhosis

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms4
  • Trials8
  • Signals20
  • Integrity notices10
  • Similar companies6

Intelligence